Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager
August 17, 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
August 16, 2022 08:01 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to...
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 12, 2022 07:30 ET
|
Ocugen
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - ...
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
August 08, 2022 16:03 ET
|
Oyster Point Pharma, Inc.
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
August 05, 2022 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022
August 03, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022
July 27, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
July 26, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- CLS-AX Dosing Completed in Cohorts 3 and 4 - - Final OASIS Data Expected in Q4 2022 - ALPHARETTA, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a...
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
July 26, 2022 06:15 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the...